Shots:
- Kyowa Kirin to receive ~$400M up front and an additional ~$850M as milestones along with royalties on future global sales. Both companies will share global development costs (Ex- Japan & the US)
- Amgen will responsible for the development, manufacturing, and commercialization of KHK4083 for all markets globally (Ex-Japan, where Kyowa Kirin will retain all rights) and also plans to utilize the data from its deCODE Genetics subsidiary for KHK4083 in other indications
- Kyowa Kirin will co-promote KHK4083 with Amgen in the US and have opt-in rights to co-promote KHK4083 in other markets outside the US including the EU and Asia
Click here to read full press release/ article | Ref: PR Newswire | Image: Wall Street Journal
The post Amgen and Kyowa Kirin Collaborate to Develop and Commercialize KHK4083 for Atopic Dermatitis first appeared on PharmaShots.
